SEER · Seer, Inc.

Current Thesis

Seer’s take-private thesis failed its published price condition at the 2026-09-18 close of $1.86; a definitive acquisition agreement would establish a new transaction case. The prior research threshold was $1.95, identified with the 2026-07-06 gap shelf. As an inference about that bid-driven price structure, the narrative is dead — the September 18 close breached the condition published before this update. That finding does not establish that an acquisition is impossible.

Two disclosures change the September 6 account of company silence. Seer announced more than 100 peer-reviewed customer publications on 2026-09-16, and the Securities and Exchange Commission accepted an officer-change filing after the market close on 2026-09-18. Neither verified update establishes an acquisition agreement or an evaluation deadline. The September 18 closing price therefore cannot demonstrate the market’s response to the later filing. Seer publication announcement; September 18 filing record.

Bullish and bearish views on Seer, Inc.

The model's bull view on Seer, Inc. (SEER), in brief: Liquid assets support the transaction argument. The bear view: The published price condition failed. The adjusted daily close of $1.86 on 2026-09-18 was below the previously published $1.95 threshold. Retaining that threshold records the failure without moving the condition after the event. Revenue weakened while liquidity declined. The… Both cases follow in full.

Bull Case

• Liquid assets support the transaction argument. Seer’s 2026-08-11 results reported $209.5 million of cash, cash equivalents and investments at 2026-06-30. This is the disclosed financial resource behind the acquisition debate; it is not a current liquidation valuation or a guaranteed distribution.
• Proposals documented interest in acquisition. Seer’s 2026-07-30 announcement confirmed revised non-binding proposals, including the Radoff-JEC cash offer of $2.55 per Class A share and Omid Farokhzad’s $2.45 cash offer with contingent value rights (CVRs). Those historical proposals establish bidder interest, but do not establish executable terms today. Seer’s proposal announcement.
• Scientific adoption has documented evidence. On 2026-09-16, Seer reported that its Proteograph technology had been used in more than 100 peer-reviewed publications. This measures published research use; the announcement does not establish a corresponding revenue increase. Seer’s announcement.

Bear Case

• The published price condition failed. The adjusted daily close of $1.86 on 2026-09-18 was below the previously published $1.95 threshold. Retaining that threshold records the failure without moving the condition after the event.
• Revenue weakened while liquidity declined. The 2026-08-11 results reported second-quarter revenue of $3.1 million, down 23% year over year, and a net loss of $16.9 million.
• The offer deadline already expired. Radoff-JEC’s 2026-08-13 release said its $2.55 cash-plus-CVR proposal expired unanswered on 2026-08-10. Its 2026-09-04 demand concerned director Meeta Gulyani’s resignation; that release supplied no higher acquisition price.

Setup & Price Structure

The measured market reference is the split- and dividend-adjusted 2026-09-18 daily close of $1.86. The supplied daily-bar series places it 21.5% below its 52-week high of $2.37, with a three-month price increase of 5.7% and a 14-period relative strength index (RSI) of 30.0. The positive three-month change does not undo the breach of the published $1.95 condition.

The available positioning evidence is dated: Radoff-JEC reported approximately 7.7% ownership in its 2026-09-04 letter. That disclosure does not establish subsequent ownership changes, retail participation or current short interest. No current moving-average value or systematic sentiment sample is available here; the evidence does not support a crowding conclusion.

Catalyst Calendar (next 30 days)

• 2026-09-23–2026-09-24 — Industry conference participation. Seer lists the Biomarkers, CDx & Precision Medicine US conference on these dates. This is a commercial event, with no acquisition decision attached to the listing. Seer’s conference calendar.
• 2026-10-01 — Officer transition takes effect. Edgar.tools’ account of the 2026-09-18 filing reports David Horn’s departure as president, chief financial officer and treasurer; Farokhzad becomes president, and Charles Endweiss becomes treasurer and principal financial and accounting officer. The SEC index confirms an officer-change filing, rather than a transaction announcement. Filing summary; SEC filing record.
• 2026-10-04 — Governance-demand review checkpoint. This is the previously identified checkpoint following Radoff-JEC’s 2026-09-04 resignation demand, not a company deadline. A disclosed committee timetable, counterproposal or definitive agreement would constitute new transaction evidence; the passage of this date alone would not.

No acquisition-decision date or earnings date within the next 30 days was verified as of 2026-09-20. Seer’s investor-events page lists no upcoming investor event. Investor calendar.

What Would Change Our Mind

The July gap shelf has already failed under the published test: a daily close below $1.95 invalidates the prior price thesis, and the 2026-09-18 close was $1.86. The record therefore retains the original condition instead of substituting a lower threshold.

A filed definitive agreement specifying cash consideration and enforceable CVR terms would establish a new acquisition case. A daily close back above the published $1.95 shelf would reverse the immediate price breach, but would not by itself resolve the expired offer documented on 2026-08-13. Separately, a reduction in the $16–18 million full-year revenue range reaffirmed on 2026-08-11 would invalidate that operating outlook.

Correlation Notes

This remains a single-company transaction situation. The dated catalysts are the competing proposals acknowledged on 2026-07-30, the activist demand on 2026-09-04 and the officer-change filing on 2026-09-18. No matched sector-return series or sufficiently broad event sample is available to establish correlation with medical technology shares or small-cap value. The sample is too small to support a group-move claim.